CA2397681C - Inhibiteurs calciques partiellement satures - Google Patents

Inhibiteurs calciques partiellement satures Download PDF

Info

Publication number
CA2397681C
CA2397681C CA2397681A CA2397681A CA2397681C CA 2397681 C CA2397681 C CA 2397681C CA 2397681 A CA2397681 A CA 2397681A CA 2397681 A CA2397681 A CA 2397681A CA 2397681 C CA2397681 C CA 2397681C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
aromatic
ring
rings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2397681A
Other languages
English (en)
Other versions
CA2397681A1 (fr
Inventor
Terrance P. Snutch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceuticals Inc
Original Assignee
Zalicus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zalicus Pharmaceuticals Ltd filed Critical Zalicus Pharmaceuticals Ltd
Publication of CA2397681A1 publication Critical patent/CA2397681A1/fr
Application granted granted Critical
Publication of CA2397681C publication Critical patent/CA2397681C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composé représentés par la formule (1a) ou (1b) ou leurs sels, dans lesquelles chaque Z est indépendamment N ou CH, mais un Z doit être N; dans lesquelles n?1¿ est 1 et n?2¿ est 0 ou 1; X?1¿ et X?2¿ sont des segments de liaison; Ar représente un ou deux anneaux aromatiques ou hétéroaromatiques substitués ou non substitués, et Cy représente un ou deux anneaux aliphatiques cycliques ou hétérocycliques substitués ou non substitués, ou est composé d'un anneau aliphatique cyclique ou hétérocyclique substitué ou non substitué et d'un anneau aromatique ou hétéroaromatique substitué ou non substitué; Y¿a? et Y¿b? sont deux anneaux aromatiques ou hétéroaromatiques substitués ou non substitués, ou peuvent être deux anneaux aliphatiques cycliques ou hétérocycliques substitués ou non substitués, ou sont composés d'un anneau aliphatique cyclique ou hétérocyclique substitué ou non substitué et d'un anneau aromatique ou hétéroaromatique substitué ou non substitué; à condition que lesdits anneaux ne soient pas tous les deux un phényle lorsque les deux Ar comprennent un seul anneau de phényle et X?1¿ contient moins de 5C; et à condition que la formule (1b) contienne au moins un anneau aromatique ou hétéroaromatique; 1?1¿ est 0 ou 1; R?1¿ est un alkyle (1-6C) substitué ou non substitué, un aryle (6-10C) substitué ou non substitué ou un arylalkyle (7-16C) substitué ou non substitué contenant éventuellement 1-4 hétéroatomes sélectionnés dans le groupe composé de halo, N, P, O, et S ou pouvant être indépendamment halo, OR, SR, NR¿2?, OOCR, NROCR, COR, COOR, CONR¿2?, CF¿3?, CN ou NO¿2?, R étant H ou alkyle (1-6C).
CA2397681A 1999-12-20 2000-12-20 Inhibiteurs calciques partiellement satures Expired - Fee Related CA2397681C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17276599P 1999-12-20 1999-12-20
US60/172,765 1999-12-20
US47692999A 1999-12-30 1999-12-30
US09/476,929 1999-12-30
PCT/CA2000/001558 WO2001046166A2 (fr) 1999-12-20 2000-12-20 Inhibiteurs calciques partiellement satures

Publications (2)

Publication Number Publication Date
CA2397681A1 CA2397681A1 (fr) 2001-06-28
CA2397681C true CA2397681C (fr) 2011-03-15

Family

ID=26868438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2397681A Expired - Fee Related CA2397681C (fr) 1999-12-20 2000-12-20 Inhibiteurs calciques partiellement satures

Country Status (7)

Country Link
EP (1) EP1242398A2 (fr)
JP (1) JP2003518107A (fr)
AU (1) AU784848B2 (fr)
CA (1) CA2397681C (fr)
MX (1) MXPA02006137A (fr)
NO (1) NO326939B1 (fr)
WO (1) WO2001046166A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026904T2 (en) 2003-04-24 2016-08-29 Incyte Holdings Corp Aza-spiroalkane derivatives as inhibitors of metalloproteases
CN101875961B (zh) 2003-07-22 2015-01-07 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
KR100875558B1 (ko) 2004-06-15 2008-12-23 화이자 인코포레이티드 벤즈이미다졸론 카복실산 유도체
MX2007002410A (es) 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
US7511077B2 (en) 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
GEP20094727B (en) 2005-02-22 2009-07-10 Pfizer Oxyindole derivatives as 5ht4 receptor agonists
WO2008031227A1 (fr) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Composés de diaryle piperidine utilisés en tant que bloqueurs de canaux calciques
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
EP2190844B3 (fr) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Dérivés d'imidazo[1,2-a]pyridine utilisés comme modulateurs du récepteur sérotoninergique 5-ht2a dans le traitement des troubles qui lui sont associés
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
NO2364142T3 (fr) 2008-10-28 2018-06-16
US9365553B2 (en) 2010-05-27 2016-06-14 Aska Pharmaceutical Co., Ltd. Heterocyclic compound and H1 receptor antagonist
US10307355B2 (en) 2015-04-28 2019-06-04 Conopco, Inc. N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same
MX2017013690A (es) * 2015-04-28 2018-03-02 Unilever Nv Compuestos de n-aralquilcarbonil-piperazina y -homopiperazina y composciones para el cuidado personal que comprenden los mismos.
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703071A (en) * 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
DE4111861A1 (de) * 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
DK0682664T3 (da) * 1993-12-08 2001-07-16 Alcon Lab Inc Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
JP2002504134A (ja) * 1997-06-16 2002-02-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 疼痛を治療するためのドラフラジン類似体の使用
WO1999043658A1 (fr) * 1998-02-27 1999-09-02 Warner-Lambert Company Agents d'aniline heterocyclique substituee bloquant les canaux de calcium
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers

Also Published As

Publication number Publication date
AU784848B2 (en) 2006-07-06
WO2001046166A3 (fr) 2002-03-07
NO20022948L (no) 2002-08-19
NO20022948D0 (no) 2002-06-19
EP1242398A2 (fr) 2002-09-25
AU2495701A (en) 2001-07-03
JP2003518107A (ja) 2003-06-03
NO326939B1 (no) 2009-03-16
CA2397681A1 (fr) 2001-06-28
MXPA02006137A (es) 2002-12-05
WO2001046166A2 (fr) 2001-06-28

Similar Documents

Publication Publication Date Title
US6492375B2 (en) Partially saturated calcium channel blockers
US6617322B2 (en) Preferentially substituted calcium channel blockers
EP1091737B1 (fr) Usage de la 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine pour le traitement de la douleur
AU785292B2 (en) Fused ring calcium channel blockers
CA2397681C (fr) Inhibiteurs calciques partiellement satures
US20040192703A1 (en) Preferentially substituted calcium channel blockers
US7244758B2 (en) N-type calcium channel blockers
US20040147529A1 (en) Preferentially substituted calcium channel blockers
US20040259866A1 (en) Calcium channel blockers comprising two benzhydril moieties
IL150117A (en) Substituted piperazine and piperidine calcium channel blockers

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141222